Summary:
A phase 4 multicenter, open-label, pilot study of two medications for treatment response in patients with shingles pain (Postherpetic Neuralgia(PHN)).
Qualified Participants Must:
• Be at least 18 years of age
•
Have pain present for more than 3 months after the healing of the herpes zoster skin rash
•
Be able to complete the treatment plan, laboratory tests, and all questionnaires